Sinovac Biotech Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sinovac Biotech Ltd.
Touting its coronavirus vaccines as a "global public good", China is quietly preparing for the first general approvals and launches, possibly within weeks, developers say. But who will be first in line to receive them? And at what cost? Distribution and pricing are just some of the unanswered questions.
Clearance by UK regulator allows trial to restart, with pivotal US trial hoped to follow suit to keep AstraZeneca and Oxford's candidate on track for a potential late 2020 readout. Plus, new results with Sinovac's vaccine in the elderly and progress with antibodies.
Cold chain distribution requirements are a major downside for mRNA-based vaccines, but Moderna may have the edge over Pfizer/BioNTech's candidate.
As China gears up to the possible launch of its first vaccines against the coronavirus, supported by clearer regulations, many see the candidates as promising and cost-effective, although they may need more convincing data to be widely adopted. Relatively low projected per dose costs are generating interest in trials in multiple countries.
- In Vitro Diagnostics
- Drug Delivery
- Implantable Devices
- Monitoring Equipment & Devices
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Beijing Kexing Bioproducts
- Sinovac Dalian Vaccine Technology Co., Ltd.
- Sinovac (Cayman) Limited